Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

Author's Avatar
Mar 29, 2023
  • Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)